The results provide new insight into the oncofunction of SMC4 and the mechanisms by which the TGFβ/Smad pathway is hyperactivated in gliomas, indicating that SMC4 is a valuable prognostic factor and potential target in glioma drug therapy. Here, TGFB1 is linked to central nervous system cancer.